SK11062003A3 - Nové kyanosubstituované dihydropyrimidínové zlúčeniny a ich použitie na liečenie chorôb - Google Patents

Nové kyanosubstituované dihydropyrimidínové zlúčeniny a ich použitie na liečenie chorôb Download PDF

Info

Publication number
SK11062003A3
SK11062003A3 SK1106-2003A SK11062003A SK11062003A3 SK 11062003 A3 SK11062003 A3 SK 11062003A3 SK 11062003 A SK11062003 A SK 11062003A SK 11062003 A3 SK11062003 A3 SK 11062003A3
Authority
SK
Slovakia
Prior art keywords
methyl
cyano
oxo
dihydro
pyrimidine
Prior art date
Application number
SK1106-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Spencer David Kimball
Louis John Lombardo
David B. Rawlins
Hai-Yun Xiao
Robert Joseph Schmidt
David Kent Williams
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of SK11062003A3 publication Critical patent/SK11062003A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK1106-2003A 2001-03-29 2002-03-26 Nové kyanosubstituované dihydropyrimidínové zlúčeniny a ich použitie na liečenie chorôb SK11062003A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27995601P 2001-03-29 2001-03-29
PCT/US2002/009497 WO2002079149A2 (en) 2001-03-29 2002-03-26 Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases

Publications (1)

Publication Number Publication Date
SK11062003A3 true SK11062003A3 (sk) 2004-08-03

Family

ID=23071059

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1106-2003A SK11062003A3 (sk) 2001-03-29 2002-03-26 Nové kyanosubstituované dihydropyrimidínové zlúčeniny a ich použitie na liečenie chorôb

Country Status (26)

Country Link
US (1) US6809102B2 (zh)
EP (1) EP1373221A4 (zh)
JP (1) JP2005504725A (zh)
KR (1) KR20030086327A (zh)
CN (1) CN1507435A (zh)
AR (1) AR034585A1 (zh)
BG (1) BG108180A (zh)
BR (1) BR0208405A (zh)
CA (1) CA2442482A1 (zh)
CZ (1) CZ20032645A3 (zh)
EE (1) EE200300474A (zh)
HR (1) HRP20030875A2 (zh)
HU (1) HUP0400350A3 (zh)
IL (1) IL157441A0 (zh)
IS (1) IS6967A (zh)
MX (1) MXPA03008634A (zh)
NO (1) NO20034300L (zh)
PE (1) PE20021013A1 (zh)
PL (1) PL373759A1 (zh)
RU (1) RU2003130961A (zh)
SK (1) SK11062003A3 (zh)
TW (1) TWI228416B (zh)
UY (1) UY27232A1 (zh)
WO (1) WO2002079149A2 (zh)
YU (1) YU75803A (zh)
ZA (2) ZA200306648B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900214B2 (en) * 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
CA2469801C (en) * 2001-12-11 2011-06-21 Kyowa Hakko Kogyo Co., Ltd. Thiadiazoline derivative
ES2326647T3 (es) * 2003-03-07 2009-10-16 Astrazeneca Ab Heterociclos condensados y sus usos.
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
WO2004092147A1 (ja) 2003-04-18 2004-10-28 Kyowa Hakko Kogyo Co., Ltd. M期キネシン阻害剤
WO2004111024A1 (ja) * 2003-06-10 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. チアジアゾリン誘導体
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
WO2005007124A2 (en) 2003-07-23 2005-01-27 Bristol-Myers Squibb Company Substituted dihydropyrimidine inhibitors of calcium channel function
JP2007509074A (ja) * 2003-10-16 2007-04-12 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
AU2005263969A1 (en) * 2004-07-22 2006-01-26 Astrazeneca Ab Fused pyrimidones useful in the treatment and the prevention of cancer
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
US20080293744A1 (en) * 2004-08-18 2008-11-27 Astrazeneca Ab Enantiomers of Selected Fused Pyrimidones and Uses in the Treatment and Prevention of Cancer
WO2006060737A2 (en) * 2004-12-03 2006-06-08 Takeda San Diego, Inc. Mitotic kinesin inhibitors
TW200720265A (en) * 2005-03-22 2007-06-01 Kyowa Hakko Kogyo Kk Agent for treatment of hematopoietic tumor
US20080194653A1 (en) * 2005-03-22 2008-08-14 Kyowa Hakko Kogyo Co., Ltd. Therapeutic Agent For Solid Tumor
EP1908755A4 (en) * 2005-06-24 2009-06-24 Kyowa Hakko Kirin Co Ltd THERAPEUTIC AGENT AGAINST RESTENOSIS
DE102006002065B4 (de) * 2006-01-16 2007-11-29 Infineon Technologies Austria Ag Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand
CN110464722B (zh) * 2019-06-06 2023-05-23 暨南大学 一类小分子化合物或其药学上可接受的盐在制备抗肿瘤转移药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211198B1 (en) 1993-04-05 2001-04-03 Synaptic Pharmaceutical Corporation Dihydropyridines and new uses thereof
EE9700209A (et) 1994-11-16 1998-04-15 Synaptic Pharmaceutical Corporation Dihüdropürimidiinid ja nende kasutamine
WO1997017969A1 (en) 1995-11-16 1997-05-22 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
CA2253862A1 (en) 1996-05-16 1997-11-20 Wai C. Wong Dihydropyrimidines and uses thereof
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6080760A (en) 1997-06-18 2000-06-27 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
CA2294349A1 (en) 1997-06-18 1998-12-23 Michael A. Patane Alpha 1aadrenergic receptor antagonists
AU1403099A (en) 1997-11-14 1999-06-07 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
AU768834B2 (en) 1998-04-01 2004-01-08 Yale University A method for selectively modulating the interactions between survivin and tubulin
US6300084B1 (en) 1998-10-08 2001-10-09 The Regents Of The University Of California Anti-mitotic agent screening process
AUPQ171999A0 (en) 1999-07-20 1999-08-12 University Of Sydney, The Neurotropic virus transport
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
CZ20021428A3 (cs) 1999-10-27 2002-11-13 Cytokinetics, Inc. Způsoby a kompozice vyuľívající chinazoliny
US6617115B1 (en) 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
US6284480B1 (en) 2000-04-03 2001-09-04 Cytokinetics, Inc. Antifungal assay
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases

Also Published As

Publication number Publication date
US6809102B2 (en) 2004-10-26
EP1373221A4 (en) 2004-09-29
BG108180A (en) 2004-09-30
EP1373221A2 (en) 2004-01-02
IS6967A (is) 2003-09-24
EE200300474A (et) 2003-12-15
HRP20030875A2 (en) 2004-08-31
AR034585A1 (es) 2004-03-03
RU2003130961A (ru) 2005-04-10
NO20034300L (no) 2003-11-07
BR0208405A (pt) 2004-03-30
HUP0400350A2 (hu) 2005-01-28
PL373759A1 (en) 2005-09-05
CA2442482A1 (en) 2002-10-10
WO2002079149A2 (en) 2002-10-10
ZA200307320B (en) 2004-12-20
ZA200306648B (en) 2004-11-26
TWI228416B (en) 2005-03-01
YU75803A (sh) 2006-05-25
WO2002079149A3 (en) 2003-02-27
CZ20032645A3 (cs) 2004-06-16
HUP0400350A3 (en) 2005-06-28
IL157441A0 (en) 2004-03-28
US20030008888A1 (en) 2003-01-09
CN1507435A (zh) 2004-06-23
KR20030086327A (ko) 2003-11-07
NO20034300D0 (no) 2003-09-26
PE20021013A1 (es) 2002-11-10
UY27232A1 (es) 2002-11-29
MXPA03008634A (es) 2003-12-08
JP2005504725A (ja) 2005-02-17

Similar Documents

Publication Publication Date Title
US6809102B2 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6900214B2 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
JP4394442B2 (ja) 抗炎症剤として有用なスピロ−ヒダントイン化合物
AU2002249389B2 (en) Inhibitors of cyclin dependent kinases as anti-cancer agent
CA2701150C (fr) Derives de quinazolinedione, leur preparation et leurs applications therapeutiques
US20020165240A1 (en) Method of treating proliferative diseases using Eg5 inhibitors
ZA200106584B (en) Triazole compounds with dopamine-D3-receptor affinity.
KR20060072142A (ko) Crf 길항제 및 이환식 복소환 화합물
KR20090115749A (ko) 우레이드기와 아미노카르보닐기를 치환기로서 갖는 신규 피롤 유도체
JPH05194477A (ja) 医薬用化合物
AU2014234907B2 (en) Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors
KR20190027383A (ko) 아폽토시스 억제제
JP2002544272A (ja) 置換3−ピリジル−4−アリールピロール並びに関連した治療及び予防法
CA3002875A1 (en) Pyridone derivatives and their use as kinase inhibitors
AU2002258636A1 (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
AU2002303169A1 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US4343801A (en) 1,2,4-Triazine derivatives, and their production and use
CA2161436A1 (en) Antiproliferative naphthyridines
KR20190139640A (ko) AIMP2-DX2와 K-Ras의 결합을 저해하는 화합물을 포함하는 고형암 예방 또는 치료용 조성물 및 AIMP2-DX2와 K-Ras의 결합을 저해하는 신규 화합물
WO2023212239A1 (en) Compositions useful for modulating splicing
Mohareb et al. Heterocyclic synthesis with ethyl α‐(3‐carbamoyl‐4, 5, 6, 7‐tetrahydrobenzo [b] thiophen‐2‐ylhydrazono) acetates: An expeditious synthetic approach to polyfunctionally substituted pyran, pyridine, and pyridazine derivatives
AU2002248724A1 (en) A method of treating proliferative diseases using Eg5 inhibitors

Legal Events

Date Code Title Description
FB9A Suspension of patent application procedure